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Abstract
Background: Efficiently delivered interventions to reduce HIV, malaria, and diarrhea are essential to accelerating global
health efforts. A 2008 community integrated prevention campaign in Western Province, Kenya, reached 47,000 individuals
over 7 days, providing HIV testing and counseling, water filters, insecticide-treated bed nets, condoms, and for HIV-infected
individuals cotrimoxazole prophylaxis and referral for ongoing care. We modeled the potential cost-effectiveness of a
scaled-up integrated prevention campaign.
Methods: We estimated averted deaths and disability-adjusted life years (DALYs) based on published data on baseline
mortality and morbidity and on the protective effect of interventions, including antiretroviral therapy. We incorporate a
previously estimated scaled-up campaign cost. We used published costs of medical care to estimate savings from averted
illness (for all three diseases) and the added costs of initiating treatment earlier in the course of HIV disease.
Results: Per 1000 participants, projected reductions in cases of diarrhea, malaria, and HIV infection avert an estimated 16.3
deaths, 359 DALYs and $85,113 in medical care costs. Earlier care for HIV-infected persons adds an estimated 82 DALYs
averted (to a total of 442), at a cost of $37,097 (reducing total averted costs to $48,015). Accounting for the estimated
campaign cost of $32,000, the campaign saves an estimated $16,015 per 1000 participants. In multivariate sensitivity
analyses, 83% of simulations result in net savings, and 93% in a cost per DALY averted of less than $20.
Discussion: A mass, rapidly implemented campaign for HIV testing, safe water, and malaria control appears economically
attractive.
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Introduction
The potential role of cost-effectiveness analysis in global health
decision-making is increasingly recognized [1]. Interventions vary
substantially in their ability to deliver health value per amount
expended. The value of global health spending can be maximized
by prioritizing cost-effective interventions [2].
Differences in cost-effectiveness reflect several factors: the
prevalence and severity of disease, the protective effect offered by
interventions, and — the only factor substantially under operational
control — how efficiently services are delivered. Innovations in
delivery strategies may offer substantial savings in cost per person
served, as well as greater coverage. These strategies may include a
community or health facility focus, as well as streamlining of health
care processes [3–5]. They can include multiple disease interven-
tions delivered simultaneously, offering the potential to share fixed
costs (such as reaching into communities) while addressing multiple
high disease burdens. However, little attention has been paid to the
economics of multi-disease intervention delivery.
In a separate report, we examined the cost of a multi-disease 7-
day integrated prevention campaign (IPC) in Western Province,
Kenya, that was implemented in 2008 in 30 village centers [6,7].
The IPC provided HIV testing and counseling, water filters,
insecticide-treated bed nets, condoms, and for HIV-infected
individuals CD4 count enumeration, 3 months of cotrimoxazole,
and referral to care. Ongoing community mobilization, including
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8health education, was conducted during the campaign, as well as in
the preceding month. More than 40,000 (80%) of targeted adults
were reached [6]. Full details of the campaign have been published
previously [6]. We calculated a cost of $42 per person served for this
initial implementation. We further estimated a cost of $32 per
person for a scaled-up campaign relying fully on Kenyan staff and
using a leaner management structure, as shown possible in a
subsequent campaign [7].The unitcost per personfor the scaled-up
campaign was estimated to be $6.27 for malaria (nets, education,
and training), $15.80 ($2.55 per person-year) for diarrhea (filters,
education, and training), and $9.92 for HIV (test kits, counseling,
condoms, education, and CD4 testing). These estimated costs
compare favorably with prior unit costs of bed nets ($6–27) [8–10],
filters ($3 per person-year) [11], and HIV VCT ($7–101) [5,12–16].
The cost-effectiveness of these interventions, delivered separate-
ly, has been assessed – for example, bed nets $14–42 per disability-
adjusted life year (DALY) averted [8,17], filters $142 per DALY
averted [11], and HIV testing $13–18 per DALY averted [13].
The cost-effectiveness of these interventions delivered in combi-
nation is unknown. However, provision of a multi-disease in-
tervention package including ART, cotrimoxazole prophylaxis,
and bed nets has been shown to provide synergistic benefits for
AIDS and malaria [18,19]. To provide further information for
policy makers, we estimated the health impact and cost-
effectiveness of delivering an integrated, community-level, multi-
disease prevention campaign in rural Kenya.
Methods
Overview
We estimated the health impact, cost, and cost-effectiveness of
the integrated multi-disease prevention campaign using a
spreadsheet-based model constructed for this purpose. We relied
on a post-campaign survey to confirm high coverage in the district
and to estimate the number of individuals directly benefiting from
distributed commodities. We derived baseline morbidity and
mortality from regional and local epidemiologic data, and es-
timated the protective effects of interventions from published
community trials. We estimated disability-adjusted life years
(DALYs) based on reductions in life years lost to mortality and
in illness episodes, weighted by published disability levels. We
incorporated an estimated campaign cost of $32 per participant
based on financial records and adjustments for scale-up (reported
separately and summarized here). Finally, we used published data
on costs of health care to estimate savings due to averted disease
and added costs due to earlier HIV treatment.
Model structure
The model was constructed for this analysis in a spreadsheet
(Excel, Microsoft Corporation, 2002). The model portrays health
benefits and averted costs due to averted disease separately
for malaria (due to long-lasting impregnated nets (LLIN)), diarrhea
(due to filters), and HIV (due to voluntary counseling and testing
(VCT) and condoms). Since these conditions are predominantly
unrelated (i.e., in different individuals), we assume independence,
which is conservative since interdependence would amplify the
health impact of interventions. We used the following calculations:
DALYs averted~N   B   F   Df   Pfz

1{F ðÞ   Dn   PnÞ M   Y
ð1Þ
Where:
N=number who benefit per campaign participant
B=baseline cases of this disease per year per individual
benefiting
F=proportion of cases that are fatal
Df=DALYs incurred with each fatality
Pf=protective effect against mortality
Dn=DALYs incurred with each non-fatal case
Pn=protective effect against non-fatal cases
M=multiplier to capture secondary benefits
Y=duration of benefit (in years)
Costs averted~N   B   F   Cf   Pfz

1{F ðÞ   Cn   PnÞ M   Y
ð2Þ
Where:
Cf=costs for health care incurred with each fatality
Cn=costs for health care incurred with each non-fatal case
The model also estimates the health and cost effects of changed
level of use of anti-retroviral therapy (ART). The campaign
accelerates use of ART through earlier detection of infected
individuals, with a CD4 count closer to the recommended level
for initiation of ART. It may also increase the lifetime use of ART
by avoiding deaths prior to HIV diagnosis. This higher ART use
extends life (thus averting DALYs), and adds costs. The campaign
likely delays the use of ART by slowing the decline in CD4 count,
through two mechanisms: prevention of malaria episodes, which
cause drops in CD4 count; and distribution of cotrimoxazole,
which slows CD4 decline. These delays in ART use extend life
(averting DALYs) and also avert costs. Finally, we estimate the
effect of the net changed time on ART on HIV transmission
(which is suppressed by ART use).
Each calculation of the effect on ART use requires several types
of inputs: biological factors (e.g., CD4 count at detection of
infection, and rates of CD4 decline), intervention effects (e.g.,
cotrimoxazole effect on rate of CD4 decline), and behaviors (e.g.,
starting ART if referred). Key input values are presented below.
Calculation methods are presented in a technical supplement
posted online (Supporting Information S1) and available from the
authors.
Data inputs
Table 1 presents data inputs, with base case values and sources,
for the malaria, diarrhea, and HIV prevention analyses. Table 2
presents key data inputs, values, and sources for the analysis of
HIV treatment and health status.
Health inputs. The number of individuals who benefit per
campaign participant for malaria and diarrhea reflects a mean of
2.5 participants per household and 7.7 members per household
respectively (both derived from the post-campaign survey). Thus, a
mean of 3.1 (=7.7/2.5) individuals benefit per campaign
participant. This number is lower for malaria (2.9) due to bed
nets obtained from non-campaign sources. For HIV, the number
benefiting per participant (0.95) is the proportion that were HIV
tested, and the number benefiting from condoms (0.36) reflects the
percent of participants reporting use of campaign-distributed
condoms.
The baseline cases of disease per individual derive from
published estimates for sub-Saharan Africa and studies conducted
in nearby geographic areas (e.g., Uganda). We estimate 0.3
malaria episodes [18,20] and 1.75 diarrhea episodes [21–24] per
person per year. For HIV, estimated annual risk per campaign
participant from persons found HIV-positive to others is 0.0038,
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4.7% prevalence, from the post-campaign survey and consistent
with a national AIDS survey [26]; and to persons found HIV-
negative is 0.009, based on HIV incidence imputed from
prevalence with assumption of random mixing [27]. Fatality rates
for malaria and diarrhea are less than 1% (for all ages, occurring
mostly in children) [20–24], and for HIV is 100% (over 10 or more
years) (assumption).
The DALYs incurred per fatal case of malaria or diarrhea is 28
[24]. For non-fatal cases, the DALY burden is the disability weight
(0.192 for malaria; 0.105 for diarrhea) [24] times an assumed
duration of disease of 1 week [28]. For HIV the DALY burden of a
death is only 8, due to the 12–15 year anticipated survival with
antiretroviral therapy [29].
The protective effect of bed nets against malaria mortality is set
at 50% (the same as for incidence). This is a conservative estimate
based on a 17% reduction in all-cause mortality [30] and malaria
representing only 9% of mortality ,14 years old [24]. The
protective effect of filters on diarrhea is 63% for morbidity [11],
and we assume the same for mortality. For HIV, by ‘‘death
averted’’ we mean an infection averted. The protection from VCT
is conservatively 50% (in positives only) [31] and by condoms is
26% (in negatives only, among the 36% using the condoms, based
on the number of condoms provided and 80% protection when a
condom is used) [32]. For HIV, each infection averted is assumed
to directly avert an average of one additional HIV infection in an
epidemic with stable HIV prevalence; this would be a secondary
benefit of the HIV interventions in the IPC. To capture this
benefit we included a multiplier, which we conservatively set at 2
for HIV, confirmed with analyses using our published epidemic
model, which predicts a 2.0 multiplier after 10 years [33]. For
malaria and diarrhea, we assumed the interventions used in the
IPC (bed nets and filters, respectively) would not have secondary
prevention benefits, i.e., each episode averted would not avert any
additional episodes. This approach reflects our reliance on
community-wide rather than individual effectiveness studies for
filters and nets. Further, malaria modeling suggests that current
infections averted may not have enduring epidemic benefits [34].
The duration of benefit for bed nets is 3 years [10,35], and for
filters is estimated at 2 years (less than lab data imply) [36]. For HIV
riskreduction,oneyearofbenefitisassumed forVCT,reflectingthe
longest duration of follow-up reported in a recent systematic review
[31]. For condoms, we also employed a one-year time frame, using
the number of distributed condoms to calculate the incremental
probability of protected sex episodes over one year.
For the analysis of earlier use of ART, assumptions were as follows
(key inputs reported in Table 2). In the campaign, 13 of 88 (14.8%)
of a sample of individuals testing positive had a CD4 count less than
250, a commonly used starting level for ART. (We explore the effect
of starting ART at CD4,350 through sensitivity analysis). We
Table 2. Value of model inputs for treatment and health
status in HIV+ individuals, Integrated Prevention Campaign,
Western Province, Kenya, 2008.
Value Sources
Ae Seek ART care early 0.60 [26], expert
opinion
Ai Lifetime increase in use of
ART due to IPC
0.15 Expert
opinion
Ma Malaria cases averted by
LLIN per HIV+ person
0.6 [18,30]
Ca CD4 drop averted per malaria
event averted (absolute)
40 [19]
Cr Reduction in CD4 drop with
CTX (proportionate)
0.62 [39]
H HIV infections transmitted per
year not on ART
0.05 [27,31]
doi:10.1371/journal.pone.0031316.t002
Table 1. Value of model inputs for prevention, Integrated Prevention Campaign, Western Province, Kenya, 2008.
Malaria Diarrhea HIV Source(s)
LLIN Filters VCT Condoms LLIN Filters VCT/Condoms
Health inputs
N number who benefit per campaign
participant
2.9 3.1 0.95 0.36 Post-campaign
survey
Post-campaign
survey
Post-campaign survey
B baseline cases of this disease per year
per individual benefiting
0.30 1.75 0.0038 0.009 [18,20] [21–24] [25–27], Post-campaign
survey (see text)
F proportion of cases that are fatal 0.0033 0.0010 1.0 1.0 [20,22] [21–24] Assumption
Df DALYs incurred with each fatal case 30 30 8 8 [24] [24] [29]
Dn DALYs incurred with each non-fatal case 0.0037 0.0020 n/a n/a [24], expert opinion [24,28] N/a
Pf protective effect against mortality 0.50 0.63 0.50 0.26 [30], expert opinion [11] [31,32]
Pn protective effect against non-fatal cases 0.50 0.63 n/a n/a [30] [11] N/a
M multiplier to capture secondary benefits n/a n/a 2 2 [34] N/a [33] (see text)
Y duration of benefit (in years) 3 2 1 1 [10,35] [36] [31]
Cost inputs
Cf costs for health care incurred with
each fatality
$65 $104 $5,092 $5,092 [40,41] [42] [29] (see text)
Cn costs for health care incurred with each
non-fatal case
$7.80 $7.00 n/a n/a [43] [42] N/a
doi:10.1371/journal.pone.0031316.t001
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conservatively one year before they would have otherwise [26]. We
estimated the resulting averted DALYs at 0.75, from clinical
modelingstudies[37,38].LifetimeincreaseduseofART duetotheIPC
(e.g., by avoiding death before HIV diagnosis) is estimated at 15%,
based on expert opinion (author JM) considering current and
projected lifetime prevalence of ART use. Each additional person
on ART averts 7.5 DALYs (discounted, over a lifetime) [29].
Bed nets may delay the need for ART by reducing episodes of
malaria, which have been associated with an average 40 point
decline inCD4[19].Thisresultsinanapproximatelyone-thirdyear
delay to need ART.
Cotrimoxazole also may delay the need for ART, based on a
study showing a 62% reduction in the rate of decline of CD4 [39].
We apply this reduction after the protection afforded by bed nets,
resulting in a further 0.49 year delay in starting ART.
The aggregate effects of the earlier, increased, and delayed ART
use described above is 15.1 added years not on ART per 1000
campaign participants. This increases HIV transmission by an
estimated 0.75 infections per 1000 participants (separate from the
HIVpreventioneffectsdiscussedabove).Technicaldetailsrelatedto
our modeling of the impact of the IPC on HIV treatment are
included ina technical supplement (seeSupporting InformationS1).
Cost inputs. We estimated the costs for health care incurred
with each malaria and diarrhea fatality based on the direct
medical costs of inpatient treatment for each disease, assuming
that fatal cases are likely to use inpatient care. The cost of health
care (Table 1) is estimated at $65 per fatality for malaria [40,41]
and $104 for diarrhea [42]. For HIV, the costs of health care per
fatality are estimated at $5092, based on a 2009 analysis of lifetime
costs adjusted for lower annual ART costs ($564) in Zambia in a
current analysis [29]. For non-fatal cases, the costs are $7.80 per
case for malaria (using a relatively expensive drug, co-artem) [43]
and $7 for diarrhea [42], for each assuming outpatient treatment,
including the cost of a clinic visit, medications and tests.
The cost of a scaled-up IPC is estimated at $32 per participant
[7]. The original campaign cost $42 per participant. A scaled-up
campaign will have lower costs through reliance on local rather
then foreign managers and a lower manager concentration, as well
as returns to scale for the publicity component. These adjustments
were initially modeled, and then confirmed in a small subsequent
campaign and with price bids for a large campaign [7].
Sensitivity analyses
We conducted one-way and multivariate sensitivity analyses to
assess the importance of uncertainty in input values. To set the
uncertainty ranges, we used a 95% confidence interval (CI) when
available. For values based directly on empirical data but lacking
formal CIs, we used a range of plus or minus one-third of the base
case. For values derived indirectly from empirical data or from
expert opinion, we used a range of plus or minus one-half. For
DALYs due to early death for malaria and diarrhea, we examine
down to 25 to reflect potential short-term competing mortality.
The multivariate analysis was a Monte Carlo simulation
conducted with Crystal Ball, Decision Engineering  2000.
We used the reported ranges distributed in truncated normal
curves. We assumed a 95% correlation of this variable with lifetime
cost of treating HIV. Simulation results reflect 100,000 trials.
Results
Disease averted
The model estimates that the IPC averts 16.3 deaths: 4.31 from
malaria, 6.81 from diarrhea, and 5.22 from HIV. There are an
additional 1304 averted episodes of malaria and 6780 of diarrhea.
DALYs averted
The prevention elements of the campaign avert an estimated
359 DALYs per 1000 participants (Table 3). Most of these benefits
(53%) derive from decreased diarrhea, due to the protective effect
for relatively frequent disease episodes. Reduced malaria accounts
for 35% of averted DALYs, and HIV prevention 12%.
Reduced mortality contributes the vast majority (96%) of DALYs
averted through prevention. Though rare, prevented deaths avert
Table 3. Results (per 1000 campaign participants), Integrated Prevention Campaign, Western Province, Kenya, 2008.
Malaria Diarrhea HIV
LLIN Filters VCT condoms TOTAL
Disease averted
Deaths 4.31 6.81 5.22 16.3
Episodes 1304 6780 5 8090
DALYs averted
Prevention 125 191 29 13 358.5
Earlier HIV care 82 81.8
TOTAL 125 191 125 441.8
Costs averted (added)
Prevention $10.420 $48,123 $18,169 $8,400 $85,113
Earlier HIV care ($37,097) ($37,097)
TOTAL $10.420 $48,123 ($10,538) $48,015
Cost-effectiveness
Campaign cost (unadjusted) $32,000
Net cost (savings) ($16,015)
Cost per DALY averted Net savings
doi:10.1371/journal.pone.0031316.t003
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events.
Earlier HIV care results in a net of 83 averted DALYs. Thus
total DALYs averted is estimated at 442 per 1000 campaign
participants, 78% of which is from deaths averted.
Costs averted
The savings due to prevented disease are $85,113 per 1000
participants. The contribution of HIV disease is 31%, much larger
than for DALYs due to the high lifetime cost of treatment.
Diarrhea and malaria contribute 57% and 12%, respectively.
Earlier HIV care (ART) increases costs by nearly $37,100.
Thus, overall savings are $48,015.
Cost-effectiveness
The estimated campaign cost of $32,000 is less than the savings
projected by our model. Thus, in the base case, the campaign is
estimated to result in net savings of $16,015 per 1000 participants.
With net savings, the incremental cost-effectiveness ratio (ICER) is
not reported; an ICER is reported as appropriate in sensitivity
analyses. The ICER based on gross costs (unadjusted for offsetting
savings) is $72 per DALY averted.
Sensitivity analyses
We conducted univariate and multivariate sensitivity analyses.
The univariate sensitivity analyses assessed the importance of
uncertainty in individual model inputs (Tables 4, 5 and 6). DALYs
averted per 1000 participants ranged from 338 to 543. For the 37
inputs assessed, 35 retained net savings for all values; one had a net
cost per DALY averted of $0.30, and two had net cost per DALY
averted over $1.00: $2.20 and $17.42. The inputs with the largest
impact on net costs were the lifetime increase in the use of ART
($32,169 in savings to $143 in added cost); the frequency,
magnitude, and duration of benefit for diarrhea; the prevention
multiplier and duration of benefit for HIV; and cost per non-fatal
diarrhea case.
Uncertainty in baseline cases per 1000 persons (i.e., disease
incidence) showed the greatest sensitivity for diarrhea ($889 to
$31,137 in net savings), followed by HIV and then malaria
(Table 4). The proportion of cases that are fatal (for malaria and
diarrhea) had little effect, and DALYs incurred per fatal and non-
fatal case also did not affect findings significantly.
Protective effect against mortality strongly affected DALYs but
not costs. Even with no mortality benefit for diarrhea, as found in
a trial of safe water vessels in the context of weekly clinical
Table 4. One-way sensitivity analyses for health inputs, Integrated Prevention Campaign, Western Province, Kenya, 2008.
Range used for input
DALYs
averted Net cost (savings)
Cost per DALY
averted
Values Basis
Health inputs: Prevention Base case (BC) 442 ($16,015) Net savings
N # who benefit per campaign participant Malaria (LLIN) 1.9–3.9 61/3 399–485 ($12,436)–($19,622) Net savings
Diarrhea (filters) 2.1–4.1 61/3 381–505 ($629)–($31,806) Net savings
HIV - VCT 0.9–1.0 60.05 441–444 ($15,057)–($16,969) Net savings
HIV - condoms 0. 24–0.48 61/3 438–446 ($13,196)–($18,779) Net savings
B baseline cases/year per 1000 persons Malaria 200–400 61/3 400–484 ($12,540)–($19,486) Net savings
Diarrhea 1200–2300 61/3 382–502 ($889)–($31,137) Net savings
HIV transmission 2.5–5.1 61/3 433–452 ($9,933)–($22,508) Net savings
HIV acquisition 6–12 61/3 438–447 ($13,238)–($18,862) Net savings
F proportion of cases that are fatal Malaria 0.22–0.44% 61/3 402–482 ($15,930)–($16,095) Net savings
Diarrhea 0.05–0.15% 61/3 353–532 ($15,683)–($16,343) Net savings
Df DALYs incurred with each fatal case Malaria 25 (lower) see text 429 - BC =BC Net savings
Diarrhea 25 (lower) see text 423 - BC =BC Net savings
HIV 4–12 61/2 424–460 =BC Net savings
Dn DALYs incurred with each non-fatal case Malaria 0.0019–0.0055 61/2 439–444 =BC Net savings
Diarrhea 0.001–0.003 61/2 435–448 =BC Net savings
Pf protective effect against mortality Malaria 0.25–0.75 61/2 382–502 ($15,837)–($16,153) Net savings
Diarrhea 0.32–0.94 61/2 354–530 ($15,664)–($16,361) Net savings
HIV transmission 0.25–0.75 61/2 428–456 ($6,929)–($25,103) Net savings
HIV acquisition 0.13–0.39 61/2 435–449 ($11,900)–($20,467) Net savings
Pn protective effect against non-fatal cases Malaria 0.33–0.67 61/3 440–443 ($12,569)–($19,468) Net savings
Diarrhea 0.51–0.72 95% CI 439–444 ($7,125)–($22,989) Net savings
M multiplier to capture secondary benefits HIV 1–3 61/2 421–463 ($2,728)–($29,299) Net savings
Y duration of benefit (in years) Malaria 2–4 61/3 400–484 ($12,540)–($19,487) Net savings
Diarrhea 1.3–2.7 61/3 375–509 $824–($32,869) $2.20 - net
savings
HIV transm. 0.5–1.5 61/2 421–463 ($2,727)–($29,298) Net savings
Note: BC=base case.
doi:10.1371/journal.pone.0031316.t004
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savings of $15,305 (not in table). Protective effect against non-fatal
cases has a moderate impact for diarrhea: 51% protection leads to
$7,125 net savings.
The sensitivity of net cost and cost per DALY averted to
campaign implementation cost and protective effect are shown
graphically in Figures 1 and 2. The net cost increases as campaign
cost rises, but remains negative until the campaign cost reaches
$48,000 per 1000 participants (Fig. 1). For the interventions’
protective effect, the net cost becomes positive below 0.81 of base
case values, and reaches a cost per DALY averted of $60 at 0.6 of
base case (Fig. 2).
Due to expanded support for starting ART at CD4,350, we
examined the implications of the higher threshold. The effects of
earlier ART initiation are modest: DALYs averted increases to
443, and savings drop to $15,539.
Our multivariate analysis (Monte Carlo simulation) suggests
that the most likely outcome is substantial health impact with net
savings, with only 17% of trials (i.e., calculation iterations) yielding
modest costs per DALY averted. The estimated DALYs averted
per 1000 participants was mean 442 (standard deviation 78),
median 435, 90% confidence interval 327–583, and range 245–
641. The mean net savings was $16,102 (median $15,306). The
90% CI was savings of $45,579 to added cost of $10,518; net
savings occurred in 83% of trials. The cost per DALY averted was
undefined at the mean (due to net savings in most trials), was less
than $20 for 93% of trials, and reached a high of $65 per DALY.
Graphic results of the multivariate analysis are included in a
technical supplement (see Supporting Information S2).
Discussion
We explored the potential health impact, net cost, and cost-
effectiveness of an integrated mass campaign to distribute
commodities and services intended to decrease malaria, diarrhea,
and HIV. We found, for each 1000 campaign participants, an
estimated health benefit of 442 disability-adjusted life years
averted, with a net savings of approximately $16,000. The
prevention component yielded 81% of the DALYs averted and
large net savings ($85,113). Earlier HIV care yielded additional
DALYs and also substantial net costs, due to the high cost of ART.
Multivariate sensitivity analyses suggest that overall health benefits
reside between 327 and 583 DALYs, the campaign is cost-saving
for more than four-fifths of simulation trials, and the cost per
DALY averted is less than $20 for 93% of trials.
Compared with the cost-effectiveness of individual interven-
tions, these results are generally more favorable. Malaria
interventions cost in the range of $2–15 per DALY averted even
for the least expensive strategies [1]. Diarrhea prevention has ten-
to 100-fold higher cost-effectiveness ratios; filters alone are
estimated at $142 per DALY averted [11]. HIV prevention is
Table 5. One-way sensitivity analyses for cost inputs, Integrated Prevention Campaign, Western Province, Kenya.
Range used for input DALYs averted Net cost (savings) Cost per DALY averted
Values Basis
Cost inputs Base case (BC) 442 ($16,015) Net savings
Cf costs for health care per fatality Malaria $33–$97 61/2 =BC ($15,875)–($16,151) Net savings
Diarrhea $54–$154 61/2 =BC ($15,672)–($16,353) Net savings
HIV $2546–$7638 61/2 =BC ($20,099)–($11,926) Net savings
Cn costs for health care per non-fatal case Malaria $3.90–$11.70 61/3 =BC ($10,943)–($21,083) Net savings
Diarrhea $3.50–$10.50 61/3 =BC $7,695–($39,720) $17.42 - net savings
Cc cost of campaign - $28,800–$35,200 61/10 =BC ($19,215)–($12,815) Net savings
Note: BC=base case.
doi:10.1371/journal.pone.0031316.t005
Table 6. One-way sensitivity analyses for inputs on treatment and health status in HIV-positive individuals, Integrated Prevention
Campaign, Western Province, Kenya.
Range used for input
DALYs
averted Net cost (savings)
Cost per DALY
averted
Values Basis
Treatment and health status in HIV+ individuals Base case (BC) 442 ($16,015) Net savings
Ae Seek ART care early HIV 0.3–0.9 61/2 439–444 ($16,658)–($15,368) Net savings
Ai Lifetime increase in use of ART due to IPC HIV 0.075–0.225 61/2 413–471 ($32,169)–$143 Net savings - $0.30
Ma Malaria cases averted by LLIN per HIV+ person Malaria-HIV 0.4–0.8 61/3 441–443 ($16,132)–($15,889) Net savings
Ca CD4 drop averted per morbid event averted HIV 13–68 95% CI 440–443 ($16,251)–($15,750) Net savings
Cr Reduction in CD4 drop with CTX HIV 0.335–0.905 95% CI 436–447 ($16,962)–($15,053) Net savings
H HIV infections transmitted per year not on ART HIV 0.025–0.075 61/2 431–437 ($8,848)–($23,200) Net savings
Ac Annual cost of ART HIV $282–$846 61/2 =BC ($17,188)–($14,838) Net savings
Note: BC=base case.
doi:10.1371/journal.pone.0031316.t006
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exceeding costs by 25- to 30-fold [33,45]. HIV care with ART
costs $500–$800 per DALY averted in Africa [29,46], and CD4
cell and viral load monitoring of ART $174 and over $5000 per
DALY averted, respectively [47].
Our analysis had several limitations. As with many cost-
effectiveness analyses, health impacts and averted care costs are
modeled rather than measured directly for the campaign.
However, empirical studies of similar interventions have shown
evidence of effectiveness in reducing morbidity and mortality over
specified time periods, which we adopted and use as the basis for
the modeled prevention benefits from the IPC. By including the
best available input values and a diversity of inputs (e.g., protective
effects for three diseases) we have mitigated this limitation.
Further, robust sensitivity analyses allowed us to assess uncertainty
in effectiveness, with favorable findings over the range of values
explored.
Second, the campaign cost is based on an economic model for
scaling up, and is 25% lower than the cost of the initial campaign
implementation. We think that uncertainty in this cost estimate is
low, based on confirmatory data from subsequent campaign
implementation and planning, and thus has little effect on our
findings. However, it will be important to observe actual costs in
a scaled up implementation. Repeat campaigns in the same
Figure 1. Sensitivity of cost and cost-effectiveness to campaign implementation cost. Integrated Prevention Campaign, Western Province,
Kenya, 2008. The base case ($32,000) is cost-saving, and net cost is positive above a campaign cost of $48,000 (not shown; outside of uncertainty
range). No cost-effectiveness ratio is calculated, due to net savings.
doi:10.1371/journal.pone.0031316.g001
Figure 2. Sensitivity of cost and cost-effectiveness to protective effect (morbidity and mortality). Integrated Prevention Campaign,
Western Province, Kenya, 2008. Net cost is positive below 81% of the base case values.
doi:10.1371/journal.pone.0031316.g002
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diagnoses, and depending on timing in relation to commodity life
spans could yield lower participation and/or health benefits.
Finally, we did not explore savings by linking this campaign to
other community campaigns, such as annual mass vitamin A
administration [48] or regular indoor residual spraying (IRS)
against malaria.
We did not include the effect of earlier ART on tuberculosis
(TB). Co-infection of HIV and TB approaches 50% in Kenya
[49], and ART may reduce TB acquisition by greater than 60%,
depending on when treatment is initiated [50]. This might suggest
substantial health gains and economic savings via TB control due
to expanded use of ART. In addition, earlier TB diagnosis might
lead to easier treatment. However, other factors complicate this
picture. Some TB infection that would be detected and treated
while under care would never have become clinically significant.
Further, ART may induce clinical worsening of TB, due to
immune reconstitution (Robin Wood, personal communication).
We believe that in the long run, expanded ART will reduce TB
transmission and thus prevalence, but in the short run the effects
are difficult to anticipate.
This analysis supports a substantial role for integrated multi-
disease mass campaigns. Such campaigns are potentially very
practical, quickly achieving high coverage of key interventions to
reduce the burden of three major diseases, with substantial health
benefits, and attractive economics. The campaigns would need
to be repeated over time in order to offer ongoing benefits. The
optimal timing is unclear, due to the differing duration of cam-
paign interventions: up to ten years for LLIN, three years for water
filters, and one year for VCT and condoms. In addition, newly
detected HIV cases will drop sharply after the initial implemen-
tation, since HIV incidence is much lower than undetected HIV
prevalence. Optimal timing would also reflect the local availability
of these services through other mechanisms. On balance, we
suspect that a three-year cycle would be desirable in most settings.
We plan to formally assess this issue in an upcoming analysis.
In conclusion, we propose expanded field implementation of
integrated multi-disease mass campaigns, coupled with rigorous
evaluation and refinement.
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